Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests
Executive Summary
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
You may also be interested in...
Spanish Team’s AI Model For Pandemic Response Named XPRIZE Winner
VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.
Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.